Aims: To evaluate the association between metformin use and heart failure (HF) exacerbation in people with type 2 diabetes (T2D) and pre-existing HF using alternative exposure models.
| INTRODUCTION
Heart failure (HF) is a serious and common comorbidity in patients with type 2 diabetes mellitus. The prevalence of HF in patients with diabetes aged ≥65 years has been reported to be as high as 22% 1 and HF in patients with diabetes is associated with 3-year mortality of 40%, 10-fold higher than that of similar patients with diabetes alone. 2 Although it remains uncertain whether or not intensive glucoselowering affects HF outcomes, 3, 4 studies have suggested that the choice of glucose-lowering agent appears to play an important role in patients with existing HF. Subgroup analyses in randomized trials evaluating incretin-based therapies including dipeptidyl peptidase-4 (DPP-
4) inhibitors (EXAMINE, SAVOR-TIMI and TECOS) and glucagon-like
peptide 1 (GLP-1) receptor agonists (ELIXA and LEADER) have not observed a significant benefit or risk related to treatment with these medications in patients with existing HF [5] [6] [7] [8] [9] ; however, two DPP-4
inhibitors (saxagliptin and alogliptin) have subsequently received US Food and Drug Administration warnings with respect to the potential risk of development of incident HF. 10 Most recently, exploratory analyses of the EMPA-REG study have suggested that substantial benefits are associated with empagliflozin in patients both with and without pre-existing HF. 11 The evidence for older agents, such as metformin and sulphonylureas, in particular, is based on far less rigorous studies and thus, reliance on clinical experience and observational evidence has been required to judge the safety and effectiveness of older anti-hyperglycaemic drugs in patients with diabetes and comorbid HF. 12 In the absence of randomized trial evidence, current observational evidence suggests that, in patients with HF, metformin is safe and its use may be associated with improved outcomes. 13 Accordingly, metformin has been considered as first-line therapy in this patient population, similarly to other populations with type 2 diabetes. 14 Nonetheless, observational studies related to the safety and effectiveness of metformin have faced a number of important methodological challenges, including how best to model time-varying drug exposure because treatment with metformin varies considerably both between patients and within-patients over time. 15 Metformin use has typically been modeled using a range of time-fixed measures (ever-use or total days of use), 13 which do not fully account for the time-varying nature of the treatment regimens and also largely misclassify exposed person-time. Indeed, these biased measures can induce immortal time bias which tends to overestimate the benefits of treatment. 16 To address the inherent challenges associated with how best to represent dynamic treatment regimens, novel analytical methods have been developed, and extensively validated, to flexibly model the effects of a time-varying cumulative history of drug use. [17] [18] [19] We hypothesize that this approach may be useful, compared with the conventional methods used in previously published studies, for more accurately modelling the association between metformin use and HF exacerbation in patients with pre-existing HF. 
| Study population
We identified those individuals who had a prescription claim for either metformin or sulphonylurea therapy from January 1, 2003 to December 31, 2009, and subsequently developed incident HF (ie, any claim with an ICD-9 CM code of 428.XX) with no previous history of a diagnosis of HF in 1 year prior to incident HF event). 20 These agents were chosen because they are the most commonly prescribed first-line oral antidiabetic agents in patients with diabetes and would provide a more homogenous study population. Moreover, this time period would avoid confounding by the newer anti-hyperglycaemic agents (sodium-glucose co-transporter-2 drugs), which were mostly unavailable on the market at this time. As thiazolidinedione therapy has been shown to increase the risk of HF, is contraindicated in patients with established HF, and was used extensively during this period of time, all patients were excluded if they has received a thiazolidinedione after diagnosis of HF. Patients also had to be aged ≥20 years and had to have at least 1 year of continuous medical insurance before diagnosis of HF (so we could be certain any cases of HF were new diagnoses) to be included in our cohort. 21 The patients were followed from the date of incident HF until death, termination of medical insurance, or December 31, 2010
(study exit date) ( Figure 1 ).
| Exposure
As patterns of glucose-lowering treatment are quite complex, we used a 
| Outcome
The time-to-event was defined as the time from the incident HF (time 0) to the first subsequent HF-related hospital admission, based on any ICD-9 code of 428.XX occurring in hospital.
FIGURE 1 Flow chart of patient exclusions
| Confounders
Covariates in our models included demographics (age and sex), history of cardiovascular disease (ischaemic heart disease, myocardial infarction, dyslipidaemia, hypertension, arrhythmia or valve disease), and a time-varying indicator of the current use of any other antidiabetic medication (sulphonylureas, incretins and insulin). We also evaluated the time-varying use of common HF drugs (ie, agents effecting the angiotensin system, β blockers, spironolactone, loop diuretics, hydralazine, digoxin and amiodarone). To further control for the clinical complexity of patients, we used specific variables and adjusted clinical groups derived from the Johns Hopkins Adjusted Clinical Group system. 22 More specifically, we adjusted for a frailty flag calculated based on patient characteristics including malnutrition, difficulty walking, dementia, incontinence and barriers to access of care. This measure of frailty has been previously validated and found accurately to identify elderly populations who have the clinical characteristics of frailty as well as to predict adverse outcomes. 23 To further control for comorbidities, we also calculated a mortality risk score based on the weighted components of the 32 adjusted diagnostic groups from the Johns Hopkins System, which has previously been shown to perform as well as or better than other comorbidity scores such as the Charlson or Elixhauser scores. 24 Additionally, we adjusted for a timevarying propensity score for metformin use that evaluates the conditional probability of metformin use based on a set of observed patient characteristics including patient demographics, healthcare service utilization, comorbidity level, and concomitant drug use (antihyperglycaemic and cardiovascular). 
| Flexible weighted cumulative exposure modelling
The novel analytical method used weighted cumulative exposure (WCE), whereby metformin exposure was modelled using a timevarying variable representing the weighted sum of the binary indicator FIGURE 2 Illustration of how metformin use was represented in conventional and weighted cumulative exposure models using a single patient's metformin exposure patterns during their follow-up period of use at each day in the relevant window of past exposure, with weights estimated to reflect the relative importance of medication taken at different times (eg, 2 days vs 10 days ago) on the current risk of events. 17 The weights assigned to past doses were estimated using a flexible cubic spline technique that avoided a priori assumptions regarding the shape of the weight function. 19 To enhance consistency with the conventional models, alternative WCE models assuming a different relevant window of past exposures of (1) 30 days and (2) 10 days were fit. For example, the 30-day window implies that metformin taken more than 1 month previously could not affect the current risk of HF exacerbation. The goodness of fit of each model were compared based on the minimum Akaike information criterion (AIC). 25 Any AIC difference > 10 was considered important, but a difference < 4 was not.
| Sensitivity analyses
A post hoc sensitivity analysis was conducted related to conventional model 3b above, where we evaluated use of metformin in the past 10 days, while also including an additional, binary, time-varying covariate which indicated if the patient had filled their first metformin prescription since the beginning of the follow-up period (ie, since incident HF diagnosis) in the last 7 days. This approach allowed us to separate the (mutually adjusted) effects of (1) any use in the past 10 days (regardless of the duration of previous exposure) vs (2) recent initiation of metformin treatment.
To improve the clinical interpretability of our results, the comparison between metformin and sulphonylurea monotherapy and its impact on HF exacerbation was conducted for the conventional timevarying current use model. This model was also re-run using metformin vs no antidiabetic agent as the comparator (the reference group in the primary analysis was metformin vs no metformin, where the no-metformin group could include any other antidiabetic agent or no antidiabetic agent [ie, diet controlled]).
| RESULTS
For the 7620 patients with diabetes with incident HF included in the present study, the mean follow-up was 604 days (1.7 years), resulting in a total of 4 606 057 person-days at risk (Figure 2 ). Their mean (SD) age was 54 (8) years, 4440 (58%) of them were men, and 6448 (85%) had three or more chronic conditions (Table 1) .
Overall, 3799 individuals (50.0%) were exposed to metformin at any point following incident HF. Table 1 shows the characteristics of
Characteristics of study cohort at time of incident heart failure (baseline a ) according to those who were exposed to metformin over the follow-up period and those who were not exposed to metformin (n = 7620) Not exposed to metformin over follow-up (n = 3821)
Exposed to metformin over follow-up (n = 3799) metformin users vs never-users; those exposed to metformin at any point during the follow-up period were healthier at baseline (ie, at time of incident HF) than those never exposed to metformin during the follow-up. Metformin users had a lower overall mortality risk score, were less likely to have valve disease or arrhythmia, had a lower mean glycated haemoglobin (HbA1c) value, were less likely to be insu- Abbreviation: HbA1c, glycated haemoglobin. a Baseline characteristics are measured in the 1 year prior to incident heart failure (HF) or are based on the most recent value of a given characteristics prior to incident HF. b For difference in baseline characteristics between those exposed to metformin over the follow-up period and those not exposed to metformin over the follow-up period.
(AIC = 14 610) among the conventional time-varying models. 
| DISCUSSION
We evaluated the relationship between metformin use and HF-related hospitalization in patients with diabetes and pre-existing HF using The arbitrary choice of the time window over which metformin exposure has been assessed in the past implies that prior knowledge regarding relative importance of exposures that occurred at different points in the past is relatively imprecise, and suggests a more datadriven approach may be required. 19 Furthermore, conventional binary indicators of any use in a particular time window (or ever-use) ignores information on dosage and duration of treatment. Although the "true" model for a particular exposure-outcome association is rarely known, statistical goodness-of-fit criteria can help identify model(s) that approximate reasonably well the underlying mechanisms. 28 It is important to emphasize again, however, that any time-fixed measures of exposure tend to induce immortal time bias which is known to produce an under-estimation of the relative risk of harm or benefit among users of a time-varying treatment. 16 There are a number of limitations to keep in mind when interpreting the results of the present study. Although WCE models provided new insights regarding the associations between exposure to metformin and the risk of HF-related hospital admission in patients with diabetes and pre-existing HF, they produced slightly wider 95% CIs than the conventional models. This is common to more complex models, where additional coefficients help to increase the accuracy of the estimated association, at the cost of increased variance. 29 Additionally,
we cannot be certain whether or not this potential acute benefit with metformin use is a true association or artifact of the data. Indeed, the potential remains for metformin (or any other antidiabetic medication)
exposure to be misclassified around the time of an event given the patient is experiencing a significant decline in their health state and unable to visit their pharmacy to fill their medication. Thus, this would make metformin appear more protective than it actually is in preventing HF-related hospitalization. The potential impact of medication adherence on our results should also be acknowledged. Sub-optimal adherence to cardiovascular medications can lead to HF exacerbations, reduced physical functioning and a higher risk of hospitalization. 30 Given that patients who are non-adherent to cardiovascular medications are also less likely to adhere to antidiabetic medications, it is plausible that those who are not exposed to metformin may actually be non-adherent to their antidiabetic medications, and thus, more likely to experience HF exacerbations compared with those who filled metformin prescriptions. This would, in turn, make it appear as though metformin use is beneficial when it is simply a marker of a patient who tends to fill their medications as directed. Last, similarly to most studies evaluating the safety of antidiabetic medications, the potential impact of confounding by indication must be considered. This is especially true when evaluating the safety of metformin given that it is typically considered as first-line therapy and its discontinuation usually indicates it is not well tolerated by the patient or the patient has more advanced diabetes (has likely progressed to insulin), both of which may be associated with poorer health outcomes. In our propensity score models, we were able to account for markers of advanced diabetes, such as insulin use in the baseline period, history of diabetes complications, HbA1c and frailty, therefore, we have balanced metformin users and non-users with respect to important confounders given the data available within the observational design. We were unable to fully account for some differences between patients, however, such as HF severity, and acknowledge that residual confounding still may be an issue.
In summary, by using alternative flexible techniques to model the impact of metformin exposure on risk of HF-related hospital admission in those with pre-existing HF and diabetes, we were able to uncover important new relationships which previous studies have not been able to elucidate and added to the literature surrounding the safety of metformin in this patient population. Indeed, our results suggest that the benefits of metformin may have been overstated in previous observational studies. While metformin was observed to be safe in this population and should be considered as an option for blood glucose control in patients with type 2 diabetes it was not found to confer the level of benefit suggested by previous studies which 
